Valeo Pharma, Inc. engages in the acquisition and in-licensing of branded pharmaceutical and hospital specialty products for sale. The company is headquartered in Kirkland, Quebec and currently employs 70 full-time employees. The firm acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The firm is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The firm's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Follow-Up Questions
Who is the CEO of Valeo Pharma Inc?
Mr. Al Moghaddam is the Chief Executive Officer of Valeo Pharma Inc, joining the firm since 2024.
What is the price performance of VPHIF stock?
The current price of VPHIF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Valeo Pharma Inc?
Valeo Pharma Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Valeo Pharma Inc market cap?
Valeo Pharma Inc's current market cap is $0
Is Valeo Pharma Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Valeo Pharma Inc, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
